Hepatitis C, Treatment and Drug Use in Australian Prison Settings
Access Status
Open access
Authors
Fetherston, James Andrew
Date
2021Supervisor
Steve Allsop
Type
Thesis
Award
PhD
Metadata
Show full item recordSchool
National Drug Research Institute
Collection
Abstract
This thesis examined issues surrounding the hepatitis C virus (HCV), its treatment, and injecting drug use as the principal risk factor for infections in Australian prison environments. Quantitative and qualitative data was collected from both former and current prisoners to explore knowledge and attitudes towards treatment. Additional data concerning drug use was collected via existing national surveys. Epidemic modelling was used to determine the potential of increased prisoner engagement in treatment.
Related items
Showing items related by title, author, creator and subject.
-
Yap, L.; Carruthers, Susan; Thompson, S.; Cheng, W.; Jones, J.; Simpson, P.; Richards, A.; Thein, H.; Haber, P.; Lloyd, A.; Butler, Tony (2014)Background: Hepatitis C virus infection (HCV) has a significant global health burden with an estimated 2%–3% of the world's population infected, and more than 350,000 dying annually from HCV-related conditions including ...
-
Hancock, Kate (2009)One consequence of the deinstitutionalisation of psychiatric care and increase in community care is the rising number of mentally ill people in prison populations where there are insufficient mental health professionals ...
-
Curtis, M.; Dietze, P.; Aitken, C.; Kirwan, A.; Kinner, S.; Butler, Tony; Stoové, M. (2018)Background: Take-home naloxone (THN) programmes are an evidence-based opioid overdose prevention initiative. Elevated opioid overdose risk following prison release means release from custody provides an ideal opportunity ...